Fluspirilen: Diphenylbutylpiperidin Neuroleptic as Weekly Depot
Fluspirilen is a potent first-generation neuroleptic (antipsychotic) from the diphenylbutylpiperidine class, similar to pimozide and penfluridol. The well-known brand name was Imap (intramuscular depot solution), which was withdrawn from the German market in 2005. Currently, fluspirilen is no longer regularly available, though it is still prescribed in some other countries.
The historical significance of fluspirilen lies in its pharmacological uniqueness as a depot antipsychotic with weekly intramuscular administration, offering considerably shorter intervals than other depot formulations such as haloperidol decanoate or risperidone long-acting. Clinically, it was used primarily in the acute phase of schizophrenia and in chronic courses with compliance difficulties. Since the introduction of newer atypical depots (risperidone, paliperidone, aripiprazole), fluspirilen has been largely displaced and eventually withdrawn from the market.
Mechanism of Action
Fluspirilen is a potent antagonist at postsynaptic dopamine D2 receptors in the mesolimbic, mesocortical, nigrostriatal, and tuberoinfundibular systems. The antipsychotic effect is mediated primarily by mesolimbic D2 blockade, which reduces positive psychotic symptoms such as hallucinations and delusions.
In addition, fluspirilen has weak anticholinergic and alpha 1 adrenergic effects, explaining typical adverse effects such as dry mouth, accommodation disturbance, and orthostatic hypotension. Like other typical neuroleptics, it increases the risk of extrapyramidal motor symptoms (EPS): parkinsonism, akathisia, acute dystonia, and tardive dyskinesia with long-term use.
Pharmacokinetically, fluspirilen is injected intramuscularly as a depot in microcrystalline form and released continuously over approximately one week. This pharmaceutical property allows once-weekly injections, which compared to daily oral therapy improves adherence.
Indications
- Acute and chronic schizophrenia: historical primary indication
- Schizoaffective disorders
- Delusional disorders: in chronic course
- Manic phases in bipolar disorder: historical
- Low-dose use in anxiety disorders: off-label, widely used in Germany in the 1980s and 1990s, no longer recommended today due to unfavorable risk-benefit ratio
In Germany, other first and second-generation antipsychotics are currently the preferred choice, with better adverse effect profiles.
Dosage and Administration
Standard dose (historical): 2 to 10 mg intramuscularly once weekly, depending on indication and individual tolerability. Up to 10 mg per week in acute symptoms, 2 to 6 mg in maintenance phase.
Administration: deep intramuscular injection into the gluteal or deltoid muscle, usually by medical personnel in a practice or clinic. Due to the microcrystal suspension, injection is sometimes painful.
Current status: Fluspirilen is no longer available on the German market. In current patients, transition to modern depot antipsychotics or oral therapy occurs under medical supervision.
Adverse Effects
Frequent: extrapyramidal motor symptoms (parkinsonism, akathisia, acute dystonia), fatigue, sedation, dry mouth, constipation, weight gain, sexual dysfunction, hyperprolactinemia with galactorrhea and amenorrhea.
Serious: tardive dyskinesia (irreversible movement disorders after prolonged use), neuroleptic malignant syndrome (rare, life-threatening, with fever, muscle rigidity, autonomic instability, altered consciousness), seizures, QT prolongation with risk of torsade de pointes, hematologic changes (agranulocytosis rare), allergic reactions.
Important: in elderly patients, use of typical antipsychotics is associated with increased mortality, particularly cardiovascular and from pneumonia. Critical risk-benefit assessment is essential before prescribing.
Drug Interactions
- QT prolonging agents (sotalol, amiodarone, erythromycin, antidepressants): additive QT prolongation, risk of torsade de pointes
- Other CNS depressants (benzodiazepines, opioids, alcohol): additive sedation and respiratory depression
- Anticholinergics (tricyclic antidepressants): additive effects with risk of confusion, urinary retention, narrow-angle glaucoma
- Antihypertensives: additive hypotension
- Levodopa: antagonistic effect, worsening of Parkinson symptoms
Special Precautions
Pregnancy: Data limited. Use only with strict indication, especially in third trimester due to extrapyramidal symptoms and neonatal adjustment disorders. Breastfeeding: not recommended as fluspirilen passes into breast milk.
In elderly patients: First-generation antipsychotics, particularly depot formulations, are only recommended in exceptional cases in elderly patients with dementia because the risk of stroke, cardiovascular events, and pneumonia is significantly increased.
Tardive dyskinesia: long-term use of typical neuroleptics can trigger irreversible movement disorders. Regular neurological examination and critical review of indications are important.
More modern alternatives: in schizophrenia, atypical second-generation antipsychotics (risperidone, olanzapine, aripiprazole, paliperidone) with better EPS profiles are now the standard treatment. Depot formulations of these agents are available.
You May Also Be Interested In
- Risperidone, atypical antipsychotic also as depot
- Paliperidone, active metabolite of risperidone as long-acting depot
- Aripiprazole, partial D2 agonist
- Haloperidol, classic butyrophenone neuroleptic
- Olanzapine, atypical antipsychotic
Frequently Asked Questions
Why was fluspirilen withdrawn from the market?
Fluspirilen was withdrawn from the German market in 2005, primarily due to unfavorable risk-benefit ratio compared to modern atypical antipsychotics. Its frequent off-label use in low doses for anxiety disorders was critically evaluated, as other therapies (SSRIs, cognitive behavioral therapy) show better efficacy and tolerability.
What are extrapyramidal motor symptoms?
EPS are movement disorders arising from dopamine receptor blockade in the striatum. They include parkinsonism (tremor, rigidity, akinesia), akathisia (motor restlessness), acute dystonias (involuntary muscle contractions, especially in face and neck), and with long-term use tardive dyskinesia (often irreversible involuntary movements).
What are the modern alternatives?
Atypical second-generation antipsychotics such as risperidone, olanzapine, quetiapine, aripiprazole, and paliperidone generally have more favorable EPS profiles and are now standard. Depot formulations are available for risperidone, paliperidone, aripiprazole, and olanzapine, with intervals ranging from 2 weeks to 3 months.
How is the transition from fluspirilen to new therapies performed?
The transition occurs under specialist supervision, usually through overlapping the last fluspirilen dose with the new antipsychotic. The choice of new agent depends on individual factors such as disease course, comorbidities, and concomitant medications.
Sources
- Gelbe Liste, Fluspirilen active substance profile (historical)
- DGPPN S3 Guideline Schizophrenia
- BfArM Market withdrawal fluspirilen 2005
- EMA Pharmacovigilance reports on typical depot antipsychotics
Legal Notice and Disclaimer
The information provided on this page is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. It does not replace the advice of a licensed physician or pharmacist. Medicines should always be taken only according to medical prescription or as dispensed by a pharmacy. All information is based on published expert information and recognized scientific sources at the time of creation; the current product information from the manufacturer is always authoritative. Sanoliste assumes no liability for completeness, timeliness, or accuracy of the information presented. In a medical emergency, call emergency number 112.